Biliary Tract Cancer
Clinical research in biliary tract cancer focuses on HER2-positive advanced and metastatic disease, with interest in treatment combinations that include chemotherapy and immune checkpoint inhibitors.
- Advanced HER2-positive disease
- Cisplatin and gemcitabine-based treatment
- PD-1/PD-L1 inhibitor combinations
The sponsor’s activity in this area centers on HER2-targeted oncology for difficult-to-treat hepatobiliary malignancies.
Breast Cancer
Research in breast cancer includes locally advanced, unresectable, recurrent, and metastatic HER2-positive disease, with additional focus on hormone receptor-positive subtypes.
- HER2-positive breast cancer
- HR-positive metastatic disease
- Endocrine therapy combinations
Trials also address palbociclib and fulvestrant combinations alongside HER2-directed therapy.
Gastroesophageal Adenocarcinoma
Studies in gastroesophageal adenocarcinoma examine HER2-positive gastric and esophageal cancers, particularly in unresectable, locally advanced, and metastatic settings.
- HER2-positive gastric cancer
- Esophageal adenocarcinoma
- Chemotherapy with HER2-targeted treatment
This area reflects a strong therapeutic interest in upper gastrointestinal oncology.
HER2-Expressing Solid Tumors
The sponsor also supports research in HER2-expressing solid tumors across locally advanced and metastatic disease, extending beyond a single tumor type.
- IHC 3+ solid tumors
- Monotherapy evaluation
- Anti-tumor activity in advanced disease
These studies broaden the sponsor’s oncology portfolio within HER2-driven cancers.
Targeted Oncology Combinations
Across its portfolio, the sponsor investigates targeted therapy combinations paired with chemotherapy and endocrine therapy in advanced solid tumors.
- HER2-directed treatment strategies
- Combination oncology regimens
- Metastatic solid tumor care
Clinical activity is concentrated in precision oncology for HER2-driven malignancies.
